サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1411932

FLT3阻害剤の市場：タイプ、製品、用途別-2024-2030年の世界予測

FLT3 Inhibitors Market by Type (FLT3-ITD (Internal Tandem Duplication), FLT3-TKD (Tyrosine Kinase Domain)), Product (Gilteritinib, Midostaurin, Quizartinib), Application - Global Forecast 2024-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 185 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.97円
FLT3阻害剤の市場：タイプ、製品、用途別-2024-2030年の世界予測
出版日: 2024年01月16日
発行: 360iResearch
ページ情報: 英文 185 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

FLT3阻害剤市場規模は2023年に4億7,529万米ドルと推定され、2024年には5億3,437万米ドルに達すると予測され、CAGR 14.98%で2030年には12億6,315万米ドルに達する見込みです。

FLT3阻害剤の世界市場

主な市場の統計
基準年[2023］ 4億7,529万米ドル
予測年 [2024] 5億3,437万米ドル
予測年 [2030] 12億6,315万米ドル
CAGR（%） 14.98%
FLT3阻害剤 Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスはFLT3阻害剤市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、FLT3阻害剤市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-FLT3阻害剤市場の市場規模および予測は？

2-FLT3阻害剤市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-FLT3阻害剤市場における技術動向と規制の枠組みは？

4-FLT3阻害剤市場における主要ベンダーの市場シェアは？

5-FLT3阻害剤市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 世界中で急性骨髄性白血病患者を治療する必要性が高まっている
      • がんの調査と治療に対する政府の支援的な取り組みと投資
    • 抑制要因
      • 高額な治療費と複雑な治療手順
    • 機会
      • FLT3阻害剤の承認情勢の改善
      • 新製品開発に向けた継続的な研究開発
    • 課題
      • FLT3阻害剤の副作用に関する懸念
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 FLT3阻害剤の市場：タイプ別

  • FLT3-ITD（内部タンデム複製）
  • FLT3-TKD（チロシンキナーゼドメイン）

第7章 FLT3阻害剤の市場：製品別

  • ギルテリチニブ
  • ミドスタウリン
  • キザルチニブ

第8章 FLT3阻害剤の市場：用途別

  • 病院とクリニック
  • 調査

第9章 南北アメリカのFLT3阻害剤の市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋地域のFLT3阻害剤の市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第11章 欧州・中東・アフリカのFLT3阻害剤の市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ主要企業別の分析

第13章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • 4SC AG
    • Actinium Pharmaceuticals, Inc.
    • AROG Pharmaceuticals, INC.
    • Astellas Pharma Inc.
    • Bayer AG
    • Biomea Fusion, Inc.
    • Daiichi Sankyo Company, Limited
    • Hanmi Pharm.Co., Ltd.
    • Mirati Therapeutics, Inc.
    • Nerviano Medical Sciences S.r.l
    • Novartis AG
    • Takeda Pharmaceuticals
    • The Menarini Group
  • 主要な製品ポートフォリオ

第14章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. FLT3 INHIBITORS MARKET RESEARCH PROCESS
  • FIGURE 2. FLT3 INHIBITORS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. FLT3 INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. FLT3 INHIBITORS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. FLT3 INHIBITORS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. FLT3 INHIBITORS MARKET DYNAMICS
  • FIGURE 7. FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 10. FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 12. FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS FLT3 INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS FLT3 INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES FLT3 INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES FLT3 INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC FLT3 INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC FLT3 INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA FLT3 INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA FLT3 INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. FLT3 INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. FLT3 INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. FLT3 INHIBITORS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. FLT3 INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL FLT3 INHIBITORS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 6. FLT3 INHIBITORS MARKET SIZE, BY FLT3-ITD (INTERNAL TANDEM DUPLICATION), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. FLT3 INHIBITORS MARKET SIZE, BY FLT3-TKD (TYROSINE KINASE DOMAIN), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 9. FLT3 INHIBITORS MARKET SIZE, BY GILTERITINIB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. FLT3 INHIBITORS MARKET SIZE, BY MIDOSTAURIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. FLT3 INHIBITORS MARKET SIZE, BY QUIZARTINIB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 13. FLT3 INHIBITORS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. FLT3 INHIBITORS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS FLT3 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 22. BRAZIL FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. CANADA FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. CANADA FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. MEXICO FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. MEXICO FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. UNITED STATES FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. UNITED STATES FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES FLT3 INHIBITORS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 35. ASIA-PACIFIC FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. ASIA-PACIFIC FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC FLT3 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 39. AUSTRALIA FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. AUSTRALIA FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. CHINA FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. CHINA FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. INDIA FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. INDIA FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. INDONESIA FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. INDONESIA FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. JAPAN FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. JAPAN FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. MALAYSIA FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. MALAYSIA FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. PHILIPPINES FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. PHILIPPINES FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. SINGAPORE FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. SINGAPORE FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. SOUTH KOREA FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. SOUTH KOREA FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. TAIWAN FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. TAIWAN FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. THAILAND FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. THAILAND FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. VIETNAM FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. VIETNAM FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA FLT3 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 79. DENMARK FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. DENMARK FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. EGYPT FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. EGYPT FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. FINLAND FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. FINLAND FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. FRANCE FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. FRANCE FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. GERMANY FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. GERMANY FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. ISRAEL FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. ISRAEL FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. ITALY FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. ITALY FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. NETHERLANDS FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. NETHERLANDS FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. NIGERIA FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. NIGERIA FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. NORWAY FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NORWAY FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. POLAND FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. POLAND FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. QATAR FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. QATAR FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 115. RUSSIA FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. RUSSIA FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. SAUDI ARABIA FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. SAUDI ARABIA FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. SOUTH AFRICA FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. SOUTH AFRICA FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. SPAIN FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SPAIN FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. SWEDEN FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SWEDEN FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 130. SWITZERLAND FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SWITZERLAND FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. TURKEY FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. TURKEY FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. UNITED ARAB EMIRATES FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. UNITED ARAB EMIRATES FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED KINGDOM FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED KINGDOM FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. FLT3 INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 143. FLT3 INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 144. FLT3 INHIBITORS MARKET LICENSE & PRICING
目次
Product Code: MRR-2E76C3E47FE8

[185 Pages Report] The FLT3 Inhibitors Market size was estimated at USD 475.29 million in 2023 and expected to reach USD 534.37 million in 2024, at a CAGR 14.98% to reach USD 1,263.15 million by 2030.

Global FLT3 Inhibitors Market

KEY MARKET STATISTICS
Base Year [2023] USD 475.29 million
Estimated Year [2024] USD 534.37 million
Forecast Year [2030] USD 1,263.15 million
CAGR (%) 14.98%
FLT3 Inhibitors Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the FLT3 Inhibitors Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the FLT3 Inhibitors Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the FLT3 Inhibitors Market, highlighting leading vendors and their innovative profiles. These include 4SC AG, Actinium Pharmaceuticals, Inc., AROG Pharmaceuticals, INC., Astellas Pharma Inc., Bayer AG, Biomea Fusion, Inc., Daiichi Sankyo Company, Limited, Hanmi Pharm.Co., Ltd., Mirati Therapeutics, Inc., Nerviano Medical Sciences S.r.l, Novartis AG, Takeda Pharmaceuticals, and The Menarini Group.

Market Segmentation & Coverage

This research report categorizes the FLT3 Inhibitors Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • FLT3-ITD (Internal Tandem Duplication)
    • FLT3-TKD (Tyrosine Kinase Domain)
  • Product
    • Gilteritinib
    • Midostaurin
    • Quizartinib
  • Application
    • Hospitals & Clinics
    • Research Laboratories
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the FLT3 Inhibitors Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the FLT3 Inhibitors Market?

3. What are the technology trends and regulatory frameworks in the FLT3 Inhibitors Market?

4. What is the market share of the leading vendors in the FLT3 Inhibitors Market?

5. Which modes and strategic moves are suitable for entering the FLT3 Inhibitors Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. FLT3 Inhibitors Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing need to treat acute myeloid leukemia patients worldwide
      • 5.1.1.2. Supportive government initiatives and investments in cancer research and treatments
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment coupled with complex treatment procedure
    • 5.1.3. Opportunities
      • 5.1.3.1. Improving approval landscape for FLT3 inhibitors
      • 5.1.3.2. Ongoing research and development for new product developments
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns relating to side impacts of FLT3 inhibitors
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. FLT3 Inhibitors Market, by Type

  • 6.1. Introduction
  • 6.2. FLT3-ITD (Internal Tandem Duplication)
  • 6.3. FLT3-TKD (Tyrosine Kinase Domain)

7. FLT3 Inhibitors Market, by Product

  • 7.1. Introduction
  • 7.2. Gilteritinib
  • 7.3. Midostaurin
  • 7.4. Quizartinib

8. FLT3 Inhibitors Market, by Application

  • 8.1. Introduction
  • 8.2. Hospitals & Clinics
  • 8.3. Research Laboratories

9. Americas FLT3 Inhibitors Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific FLT3 Inhibitors Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa FLT3 Inhibitors Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. 4SC AG
    • 13.1.2. Actinium Pharmaceuticals, Inc.
    • 13.1.3. AROG Pharmaceuticals, INC.
    • 13.1.4. Astellas Pharma Inc.
    • 13.1.5. Bayer AG
    • 13.1.6. Biomea Fusion, Inc.
    • 13.1.7. Daiichi Sankyo Company, Limited
    • 13.1.8. Hanmi Pharm.Co., Ltd.
    • 13.1.9. Mirati Therapeutics, Inc.
    • 13.1.10. Nerviano Medical Sciences S.r.l
    • 13.1.11. Novartis AG
    • 13.1.12. Takeda Pharmaceuticals
    • 13.1.13. The Menarini Group
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing